Bluejay Diagnostics is expected to report zero revenue for the third quarter of 2026 as its core Symphony platform remains pre-commercial, with consensus EPS estimates currently unavailable following a 1-for-4 reverse stock split on November 3. Investors are primarily focused on the clinical results from the SYMON-II pivotal study and the updated timeline for an FDA 510(k) submission for its rapid IL-6 sepsis test.
The company recently achieved a critical manufacturing milestone for its test cartridges, which is intended to support supply-chain readiness for future commercialization. While Bluejay strengthened its balance sheet to approximately $9.6 million in cash earlier this year, management indicated a need for significant additional capital to fund its regulatory roadmap through 2027.